The plasminogen activation system in tumor growth, invasion, and metastasis

Cellular and Molecular Life Sciences

Volumn 57, Issue 1, 2000, Pages 25-40

  Andreasen, P A ^a   Egelund, R ^a   Petersen, H H ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Anti invasive therapy; Cell migration; Integrins; Serine proteinases; Serpins

Indexed keywords

INTEGRIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; UROKINASE RECEPTOR;

BIOCHEMISTRY; CANCER INVASION; CANCER THERAPY; CELL MIGRATION; CYTOLOGY; ENZYME ACTIVITY; HUMAN; METASTASIS; MOLECULAR BIOLOGY; PLASMINOGEN ACTIVATION; PROTEIN LOCALIZATION; REVIEW; TUMOR GROWTH;

ANIMALS; CELL CULTURE TECHNIQUES; CELL DIVISION; CELL MOVEMENT; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATORS; PLASMINOGEN INACTIVATORS; SIGNAL TRANSDUCTION; VITRONECTIN;

EID: 0033981473     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s000180050497     Document Type: Review

References (197)

1. 1 Danø K., Andreasen P. A., Grøndahl-Hansen K., Kristensen P., Nielsen L. S. and Skriver L. (1985) Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res. 44: 139-266
2. 2 Mignatti P. and Rifkin D. B. (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73: 161-195
3. 3 Werb Z. (1997) ECM and cell surface proteolysis: regulating cellular ecology. Cell 91: 439-442
4. 4 Dvorak H. F., Brown L. F., Detmar M. and Dvorak A. M. (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146: 1029-1039
5. 5 Hanahan D. and Folkman J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364
6. 6 Tremblay G. (1979) Stromal aspects of breast carcinoma. Exp. Mol. Pathol. 31: 248-260
7. 7 Nagy J. A., Brown L. F., Senger D. R., Lanir N., Water L. van de, Dvorak A. M. et al. (1989) Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim. Biophys. Acta 948: 305-326
8. 8 Andreasen P. A., Georg B., Lund L. R., Riccio A. and Stacey S. N. (1990) Plasminogen activator inhibitors: hormonally regulated serpins. Mol. Cell. Endocrinol. 68: 1-19
9. 9 Andreasen P. A., Petersen L. C. and Danø K. (1991) Diversity in catalytic properties of single-chain and two-chain tissue-type plasminogen activator. Fibrinolysis 5: 207-215
10. 10 Pöllänen J., Stephens R. W. and Vaheri A. (1991) Directed plasminogen activation at the surface of normal and malignant cells. Adv. Cancer Res. 57: 273-328
11. 11 Vassalli J.-D. (1994) The urokinase receptor. Fibrinolysis 8[suppl. 1]: 172-181
12. 12 Rijken D. C. (1995) Plasminogen activators and plasminogen activator inhibitors: biochemical aspects. Bailliéres Clin. Haematol. 8: 291-312
13. 13 Andreasen P. A., Kjøller L., Christensen L. and Duffy M. J. (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72: 1-22
14. 14 Schmitt M., Harbeck N., Thomssen C., Wilhjelm O., Magdolen V., Reuning U. et al. (1997) Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemostasis 78: 285-296
15. 15 Behrendt N. and Stephens R. W. (1998) The urokinase receptor. Fibrinolysis Proteolysis 12: 191-204
16. 16 Dear A. E. and Medcalf R. L. (1995) The cellular and molecular biology of plasminogen activator inhibitor type-2. Fibrinolysis 9: 321-330
17. 17 Collen D. (1980) On the regulation of fibrinolysis. Thromb. Haemostasis 43: 77-89
18. 18 O'Reilly M. S., Holgren L., Shing Y., Chen C., Rosenthal R. A., Moses M. et al. (1994) Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79: 315-328
19. 19 Dong Z., Kumar R., Yang X. and Fidler I. J. (1997) Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88: 801-810
20. 20 Gately S., Twardowski P., Stack M. S., Cundiff D. L., Grella D., Castellino F. J. et al. (1997) The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Natl. Acad. Sci. USA 94: 10868-10872
21. 21 Patterson B. C. and Sang Q. A. (1997) Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J. Biol. Chem. 272: 28823-28825
22. 22 Stathakis P., Fitzgerald M., Matthias L. J., Chesterman C. N. and Hogg P. J. (1997) Generation of angiostatin by reduction and proteolysis of plasmin: catalysis by a plasmin reductase secreted by cultured cells. J. Biol. Chem. 272: 20641-20645
23. 23 Lijnen H. R., Ugwu F., Bini A. and Collen D. (1998) Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 37: 4699-4702
24. 24 Lucas R., Holmgren L., Garcia I., Jimenez B., Mandriota S. J., Borlat F. et al. (1998) Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 92: 4730-4741
25. 25 Petersen L. C., Lund L. R., Nielsen L. S., Dano K. and Skriver L. (1988) One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J. Biol. Chem. 263: 11189-11195
26. 26 Birchmeier C. and Gherardi E. (1998) Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 8: 404-410
27. 27 Roldan A. L., Cubellis M. V., Masucci M. T., Behrendt N., Lund L. R., Danø K. et al. (1990) Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin-dependent proteolysis. EMBO J. 9: 467-474
28. 28 Kristensen P., Eriksen J., Blasi F. and Danø K. (1991) Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J. Cell Biol. 115: 1763-1771
29. 29 Krätzschmar J., Haendler B., Kojima S., Rifkin D. B. and Schleuning W. D. (1993) Bovine urokinase-type plasminogen activator and its receptor: cloning and induction by retinoic acid. Gene 125: 177-183
30. 30 Rabbani S. A, Rajwans N., Achbarou A., Murthy K. K. and Goltzman D. (1994) Isolation and characterization of multiple isoforms of the rat urokinase receptor in osteoblasts. FEBS Lett. 338: 69-74
31. 31 Fowler B., Mackman N., Parmer R. J. and Miles L. A. (1998) Binding of human single chain urokinase to chinese hamster ovary cells and cloning of hamster uPAR. Thromb. Haemostasis 80: 148-154
32. 32 Behrendt N., Ploug M., Patthy L., Houen G., Blasi F. and Danø K. (1991) The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J. Biol. Chem. 266: 7842-7847
33. 33 Ploug M., Kjalke M., Rønne E., Weidle U., Høyer-Hansen G. and Danø K. (1993) Localization of the disulfide bonds in the NH2-terminal domain of the cellular receptor for human urokinase-type plasminogen activator: a domain structure belonging to a novel superfamily of glycolipid-anchored membrane proteins. J. Biol. Chem. 268: 17539-17546
34. 34 Ohkura N., Inoue S., Ikeda K. and Hayashi K. (1994) The two subunits of a phospholipase A2 inhibitor from the plasma of Thailand cobra having structural similarity to urokinase-type plasminogen activator receptor and LY-6 related proteins. Biochem. Biophys. Res. Commun. 204: 1212-1218
35. 35 Behrendt N., Rønne E. and Danø K. (1996) Domain interplay in the urokinase receptor: requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains. J. Biol. Chem. 271: 22885-22894
36. 36 Ploug M. and Ellis V. (1994) Structure-function relationships in the receptor for urokinase-type plasminogen activator: comparison to other members of the Ly-6 family and snake venom χ-neurotoxins. FEBS Lett. 349: 163-168
37. 37 Ploug M., Rønne E., Behrendt N., Jensen A. L., Blasi F. and Danø K. (1991) Cellular receptor for urokinase plasminogen activator: carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidyl inositol. J. Biol. Chem. 266: 1926-1933
38. 38 Lau H. K. and Kim M. (1994) Soluble urokinase receptor from fibrosarcoma HT-1080 cells. Blood Coagul. Fibrinolysis 5: 473-478
39. 39 Pedersen N., Schmitt M., Rønne E., Nicoletti M. I., Høyer-Hansen G., Conese M. et al. (1993) A ligand-free, soluble urokinase receptor is present in the ascitie fluid from patients with ovarian cancer. J. Clin. Invest. 92: 2160-2167
40. 40 Sillem M., Prifti S., Monga B., Buvari P., Shamia U. and Runnebaum B. (1997) Soluble urokinase-type plasminogen activator receptor is over-expressed in uterine endometrium from women with endometriosis. Mol. Hum. Reprod. 3: 1101-1105
41. 41 Sier C. F., Stephens R., Bizik J., Mariani A., Bassan M., Pedersen N. et al. (1998) The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res. 58: 1843-1849
42. 42 Wahlberg K., Høyer-Hansen G. and Casslén B. (1998) Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res. 58: 3294-3298
43. 43 Pyke C., Eriksen J., Solberg H., Nielsen B. S., Kristensen P., Lund L. R. et al. (1993) An alternatively spliced variant for the human receptor for urokinase plasminogen activator. FEBS Lett. 326: 69-74
44. 44 Cubellis M. V., Nolli M. L., Cassani G. and Blasi F. (1986) Binding of single chain pro-urokinase to the urokinasc receptor of human U937 cells. J. Biol. Chem. 261: 15819-15822
45. 45 Appella E., Robinson E. A., Ullrich S. J., Stoppelli M. P., Corti A., Cassani G. et al. (1987) The receptor-binding sequence of urokinase: a biological function for the growth-factor module of proteases. J. Biol. Chem. 262: 4437-4440
46. 46 Ploug M., Rahbek-Nielsen H., Ellis V., Roepstorff P. and Danø K. (1995) Chemical modification of the urokinase-type plasminogen activator and its receptor using tetranitromethane: evidence for the involvement of specific tyrosine residues in both molecules during receptor-ligand interaction. Biochemistry 34: 12524-12534
47. 47 Magdolen V., Rettenberger P., Koppitz M., Goretzki L., Kessler H., Weidle U. H. et al. (1996) Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator. Eur. J. Biochem. 237: 743-751
48. 48 Ploug M., Østergaard S., Hansen L. B., Holm A. and Danø K. (1998) Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist: evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry 37: 3612-3622
49. 49 Quax P. H., Grimbergen J. M., Lansink M., Bakker A. H., Blatter M. C, Belin D. et al. (1998) Binding of human urokinase-type plasminogen activator to its receptor: residues involved in species specificity and binding. Arterioscler. Thromb. Vasc. Biol. 18: 693-701
50. 50 Ploug M., Ellis V. and Danø K. (1994) Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate: evidence for a hydrophobic binding site exposed only on the intact receptor. Biochemistry 33: 8991-8997
51. 51 Oda M., Shiraishi A. and Hasegawa M. (1998) Analysis of the ternary complex formation of human urokinase with the separated domains of its receptor. Eur. J. Biochem. 256: 411-418
52. 52 Ploug M. (1998) Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator: residues located at equivalent positions in uPAR domains I and III participate in the assembly of a composite ligand-binding site. Biochemistry 37: 16494-16505
53. 53 Pöllänen J. (1993) The N-terminal domain of human urokinase receptor contains two distinct regions critical for ligand recognition. Blood 82: 2719-2729
54. 54 Høyer-Hansen G., Rønne E., Solberg H., Behrendt N., Ploug M., Lund L. R. et al. (1992) Urokinase plasminogen activator cleaves its cell surface receptor, releasing the ligand binding domain. J. Biol. Chem. 267: 18224-18229
55. 55 Høyer-Hansen G., Ploug M., Behrendt N., Rønne E. and Danø K. (1997) Cell-surface acceleration of urokinase-catalysed receptor cleavage. Eur. J. Biochem. 243: 21-36
56. 56 Solberg H., Rømer J., Brünner N., Holm A., Sidenius N., Danø K. et al. (1994) A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int. J. Cancer 58: 877-881
57. 57 Wei Y., Waltz D. A., Rao N., Drummond R. J., Rosenberg S. and Chapman H. A. (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269: 32380-32388
58. 58 Deng G., Curriden S. A., Wang S., Rosenberg S. and Loskutoff D. J. (1996) Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134: 1563-1571
59. 59 Kanse S. M., Kost C., Wilhelm O. G., Andreasen P. A. and Preissner K. T. (1996) The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res. 224: 344-353
60. 60 Carriero M. V., Del Vecchio S., Franco P., Potena M. I., Chiaradonna F., Botti G. et al. (1997) Vitronectin binding to urokinase receptor in human breast cancer. Clin. Cancer Res. 3: 1299-1308
61. 61 Høyer-Hansen G., Behrendt N., Ploug M., Danø. K. and Preissner K. T. (1997) The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett. 420: 79-85
62. 62 Wei Y., Lukashev M., Simon D. I., Bodary S. C., Rosenberg S., Doyle M. V. et al. (1996) Regulation of integrin function by the urokinase receptor. Science 273: 1551-1555
63. 63 Carrell R. W. and Stein P. E. (1996) The biostructural pathology of the serpins: critical functions of sheet opening mechanism. Biol. Chem. Hoppe-Seyler 377: 1-17
64. 64 Gils A. and Declerck P. J. (1998) Structure-function relationships in serpins: current concepts and controversies. Thromb. Haemostasis 80: 531-541
65. 65 Egelund R., Rodenburg K. W., Andreasen P. A., Rasmussen M. S., Guldberg R. E. and Petersen T. E. (1998) An ester bond linking a fragment of a serine proteinase to its serpin inhibitor. Biochemistry 37: 6375-6379
66. 66 Stratikos E. and Gettins P. G. (1997) Major proteinase movement upon stable serpin-protease complex formation. Proc. Natl. Acad. Sci. USA 94: 453-458
67. 67 Wilczynska M., Fa M., Karolin J., Ohlsson P. I., Johansson L. B. and Ny T. (1997) Structural insights into serpin-protease complexes reveal the inhibitory mechanism of serpins. Nat. Struct. Biol. 4: 354-357
68. 68 Stein P. E. and Chothia C. (1991) Serpin tertiary structure transformation. J. Mol. Biol. 221: 615-621
69. 69 Egelund R., Schousboe S. L., Sottrup-Jensen L., Rodenburg K. W. and Andreasen P. A. (1997) Type-1 plasminogen-activator inhibitor: conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility. Eur. J. Biochem. 248: 775-785
70. 70 Deng G., Royle G., Seiffert D. and Loskutoff D. J. (1995) The PAI-1/vitronectin interaction: two cats in a bag? Thromb. Haemostasis 74: 66-70
71. 71 Lawrence D. A., Berkenpas M. B., Palaniappan S. and Ginsburg D. (1994) Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J. Biol. Chem. 269: 15223-15228
72. 72 Van Meijer M., Gebbink R. K., Preissner K. T. and Pannekoek H. (1994) Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1). FEBS Lett. 352: 342-346
73. 73 Padmanabhan J. and Sane D. C. (1995) Localization of a vitronectin binding region of plasminogen activator inhibitor-1. Thromb. Haemostasis 73: 829-834
74. 74 Felding-Habermann B. and Cheresh D. A. (1993) Vitronectin and its receptors. Curr. Opin. Cell Biol. 5: 864-868
75. 75 Preissner K. T. and Seiffert D. (1998) Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb. Res. 89: 1-21
76. 3 binding to vitronectin. Nature 383: 441-443
77. 77 Kjøller L., Kanse S., Kirkegaard T., Rodenburg K. W., Rønne E., Goodmann S. L. et al. (1997) Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp. Cell Res. 232: 420-429
78. 78 Ciambrone G. J. and McKeown-Longo P. J. (1990) Plasminogen activator inhibitor type I stabilizes vitronectin-dependent adhesions in HT-1080 cells. J. Cell Biol. 111: 2183-2195
79. 3, integrins of fibrosarcoma cells: dependence on extracellular matrix components. Cancer Res. 57: 1682-1689
80. 80 Xue W., Kindzelskii A. L., Todd R. F. and Petty H. R. (1994) Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J. Immunol. 152: 4630-4640
81. 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J. Exp. Med. 181: 1381-1390
82. 82 Sitrin R. G., Todd R. F., Petty H. R., Brock T. G., Shollenberger S. B., Albrecht E. et al. (1996) The urokinase receptor (CD87) faciliates CD11b/CD18-mediated adhesion of human monocytes. J. Clin. Invest. 97: 1942-1951
83. 83 Myöhänen H. T., Stephens R. W., Hedman K., Tapiovaara H., Rønne E., Høyer-Hansen G. et al. (1993) Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. J. Histochem. Cytochem. 41: 1291-1301
84. 2, CD11b/CD18) during neutrophil polarization. J. Immunol. 156: 297-309
85. 85 Simons K. and Ikonen E. (1997) Functional rafts in cell membranes. Nature 387: 569-572
86. 86 Porter J. C. and Hogg N. (1998) Integrins take partners: cross-talk between integrins and other membrane receptors. Trends Cell Biol. 8: 390-396
87. 87 Stahl A. and Mueller B. M. (1995) The urokinase-type plasminogen activator receptor, a GPI-linked protein, is localized in caveolae. J. Cell Biol. 129: 335-344
88. 88 Okada S. S., Tomaszewski J. E. and Barnathan E. S. (1995) Migrating vascular smooth muscle cells polarize cell surface urokinase receptors after injury in vitro. Exp. Cell Res. 217: 180-187
89. 89 Koshelnick Y., Ehart M., Hufnagl P., Heinrich P. C. and Binder B. R. (1997) Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598. J. Biol. Chem. 272: 28563-28567
90. 90 Felez J. (1998) Plasminogen binding to cell surfaces. Fibrinolysis Proteolysis 12: 183-189
91. 91 Matrisian L. M. (1992) The matrix-degrading metalloproteinases. Bioessays 14: 455-463
92. 92 Carmeliet P., Moons L., Lijnen R., Baes M., Lemaitre V., Tipping P. et al. (1997) Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat. Genet. 17: 439-444
93. 93 Lijnen H. R., Van Hoef B., Lupu F., Moons L., Carmeliet P. and Collen D. (1998) Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler. Thromb. Vasc. Biol. 18: 1035-1045
94. 94 Lijnen H. R., Silence J., Lemmens G., Frederix L. and Collen D. (1998) Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system. Thromb. Haemost. 79: 1171-1176
95. 95 Mazzieri R., Masiero L., Zanetta L., Monea S., Onisto M., Garbisa S. et al. (1997) Control of type IV collagenase activity by components of the urokinase system: a regulatory mechanism with cell-bound reactants. EMBO J. 16: 2319-2332
96. 96 Gately S., Twardowski P., Stack M. S., Patrick M., Boggio L., Cundiff D. L. et al. (1996) Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res. 56: 4887-4890
97. 97 Resnati M., Guttinger M., Valcamonica S., Sidenius N., Blasi F. and Fazioli F. (1996) Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 15: 1572-1582
98. 98 Konakova M., Hucho F. and Schleuning W.-D. (1998) Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. Eur. J. Biochem. 253: 421-429
99. 99 Dumler I., Weis A., Mayboroda O. A., Maasch C., Jerke U., Haller H. et al. (1998) The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells. J. Biol. Chem. 273: 315-321
100. 100 Dumler I., Petri T. and Schleuning W.-D. (1993) Interaction of urokinase-type plasminogen activator (uPA) with its cellular receptor (uPAR) induces phosphorylation on tyrosine of a 38 kDa protein. FEBS Lett. 322: 37-40
101. 101 Nguyen D. H., Hussaini I. M. and Gonias S. L. (1998) Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motilily. J. Biol. Chem. 273: 8502-8507
102. 102 Tang H., Kerins D. M., Hao Q., Inagami T. and Vaughan D. E. (1998) The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J. Biol. Chem. 273: 18268-18272
103. 103 Busso N., Masur S. K., Lazega D., Waxman S. and Ossowski L. (1994) Induction of cell migration by pro-urokinase binding to its receptor: possible mechanisms for signal transduction in human epithelial cells. J. Cell Biol. 126: 259-270
104. 104 Li C, Liu J.-N. and Gurewich V. (1995) Urokinase-type plasminogen activator-induced monocyte adhesion requires a carboxyl-terminal lysine and cAMP-dependent signal transduction. J. Biol. Chem. 270: 30282-30285
105. 105 Del Rosso M., Anichini E., Pedersen N., Blasi F., Fibbi G., Pucci M. et al. (1993) Urokinase-urokinase receptor interaction: non-mitogenic signal transduction in human epidermal cells. Biochem. Biophys. Res. Commun. 190: 347-352
106. 106 Anichini E., Fibbi G., Pucci M., Caldini R., Chevanne M. and Del Rosso M. (1994) Production of second messengers following chemotactic and mitogenic urokinase-receptor interaction in human fibroblasts and mouse fibroblasts transfected with human urokinase receptor. Exp. Cell Res. 213: 438-448
107. 107 Fibbi G., Caldini R., Chevanne M., Pucci M., Schiavone N., Morbidelli L. et al. (1998) Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucletodies against the urokinase receptor. Lab. Invest. 78: 1109-1119
108. 108 Fazioli F., Resnati M., Sidenius N., Higashimoto Y., Appella E. and Blasi F. (1997) A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 16: 7279-7286
109. 109 Cubellis M. V., Andreasen P. A., Ragno P., Mayer M., Danø K. and Blasi F. (1989) Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc. Natl. Acad. Sci. USA 86: 4828-4832
110. 110 Ellis V., Wun T.-C, Behrendt N., Rønne E. and Danø K. (1990) Inhibition of receptor-bound urokinase by plasminogen activator inhibitors. J. Biol. Chem. 265: 9904-9908
111. 111 Andreasen P. A., Sottrup-Jensen L., Kjøller L., Nykjær A., Moestrup S. K., Munch Petersen C. et al. (1994) Receptor-mediated endocytosis of plasminogen activators and activator/inhibitor complexes. FEBS Lett. 338: 239-245
112. 112 Gliemann J. (1998) Receptors of the low density lipoprotein (LDL) receptor family in man: multiple functions of the large family members via interaction with complex ligands. Biol. Chem. 379: 951-964
113. 113 Neels J. G., Horn I. R., Berg B. M. M. van den, Pannekoek H. and Zonneveld A.-J. van (1998) Ligand-receptor interactions of the low density lipoprotein receptor-related protein, a multiligand endocytic receptor. Fibrinolysis Proteolysis 12: 219-240
114. 2-Macroglobulin receptor/ LDL receptor related protein (LRP)-dependent internalization of the urokinase receptor. J. Cell Biol. 131: 1609-1622
115. 115 Nykjær A., Conese M., Christensen E. I., Olson D., Cremona O., Gliemann J. et al. (1997) Recycling of the urokinase receptor upon internalization of uPA:serpin complexes. EMBO J. 16: 2610-2620
116. 116 Bu G. and Schwartz A. L. (1998) RAP, a novel type of ER chaperone. Trends Cell Biol. 8: 272-276
117. 117 Franco P., Iaccarino C., Chiaradonna F., Brandazza A., Iavarone C., Mastronicola M. R. et al. (1997) Phosphorylation of human pro-urokinase on Ser138/303 impairs its receptor-dependent ability to promote myelomonocytic adherence and motility. J. Cell Biol. 137: 779-791
118. 118 Franco P., Massa O., Garcia-Rocha M., Chiaradonna F, Iaccarinom C., Correas I. et al. (1998) Protein kinase C-dependent in vivo phosphorylation of prourokinase leads to the formation of a receptor competitive antagonist. J. Biol. Chem. 273: 27734-27740
119. 119 Nusrat A. R. and Chapman H. A. (1991) An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J. Clin. Invest. 87: 1091-1097
120. 120 Waltz D. A., Sailor L. Z. and Chapman H. A. (1993) Cytokines induce urokinase-dependent adhesion of human myeloid cells: a regulatory role for plasminogen activator inhibitors. J. Clin. Invest. 91: 1541-1552
121. 121 Waltz D. and Chapman H. (1994) Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J. Biol. Chem. 269: 14746-14750
122. 122 Stahl A. and Mueller B. M. (1997) Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int. J. Cancer 71: 116-122
123. 123 Chang A. W., Kuo A., Barnathan E. S. and Okada S. S. (1998) Urokinase receptor-dependent upregulation of smooth muscle cell adhesion to vitronectin by urokinase. Arterioscler. Thromb. Vasc. Biol. 18: 1855-1860
124. 124 Simon D. I., Rao N. K., Xu H., Wei Y., Majdic O., Rønne E. et al. (1996) Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 88: 3185-3194
125. 2 integrins in vivo. J. Exp. Med. 188: 1029-1037
126. 126 Sheetz M. P., Felsenfeld D. P. and Galbraith C. G. (1998) Cell migration: regulation of force on extracellular-matrix-integrin complexes. Trends Cell Biol. 8: 51-54
127. 127 Bretscher M. S. (1996) Moving membrane up to the front of migrating cells. Cell 85: 465-467
128. 128 Ji W. R., Castellino F. J., Chang Y., Deford M. E., Gray H., Villarreal X. et al. (1998) Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J. 12: 1731-1738
129. 129 Claesson-Welsh L., Welsh M., Ito N., Anand-Apte B., Soker S., Zetter B. et al. (1998) Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc. Natl. Acad. Sci. USA 95: 5579-5583
130. 130 Gudewicz P. W. and Gilboa N. (1987) Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem. Biophys. Res. Commun. 147: 1176-1181
131. 131 Fibbi G., Ziche M., Morbidelli L., Magnelli L. and Del Rosso M. (1988) Interaction of urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells. Exp. Cell Res. 179: 385-395
132. 132 Del Rosso M., Fibbi G., Dini G., Grappone C., Pucci M., Caldini R. et al. (1990) Role of specific membrane receptors in urokinase-dependent migration of human keratinocytes. J. Invest. Dermatol. 94: 310-316
133. 133 Odekon L. E., Sato Y. and Rifkin D. B. (1992) Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J. Cell. Physiol. 150: 258-263
134. 134 Gyetko M. R., Todd R. F., Wilkinson C. C. and Sitrin R. G. (1994) The urokinase receptor is required for human monocyte chemotaxis in vitro. J. Clin. Invest. 93: 1380-1387
135. 135 Stahl A. and Mueller B. M. (1994) Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res. 54: 3066-3071
136. 136 Okada S. S., Grobmyer S. R. and Barnathan E. S. (1996) Contrasting effects of plasminogen activators, urokinase receptor, and LDL receptor-related protein on smooth muscle cell migration and invasion. Arterioscler. Thromb. Vasc. Biol. 16: 1269-1276
137. 137 Sandberg T., Casslen B., Gustavsson B. and Benraad T. J. (1998) Human endothelial cell migration is stimulated by urokinase plasminogen activator:plasminogen activator inhibitor I complex released from endometrial stromal cells stimulated with transforming growth factor betal: possible mechanism for paracrine stimulation of endometrial angiogenesis. Biol. Reprod. 59: 759-767
138. 138 Petzelbauer E., Springhorn J. P., Tucker A. M. und Madri J. A. (1996) Role of plasminogen activator inhibitor in the reciprocal regulation of bovine aortic endothelial and smooth muscle cells migration by TGF-β1. Am. J. Pathol. 149: 923-931
139. 2-macroglobulin receptor associated protein. Thromb. Haemostasis 78: 880-886
140. 140 Weaver A. M., Hussaini I. M., Mazar A., Henkin J. and Gonias S. L. (1997) Embryonic fibroblasts that are genetically deficient in low density lipoprotein receptor-related protein demonstrate increased activity of the urokinase receptor system and accelerated migration on vitronectin. J. Biol. Chem. 272: 14372-14379
141. 141 Brückner A., Filderman A. E., Kirchheimer J. C., Binder B. R. and Remold H. G. (1992) Endogenous receptor-bound urokinase mediates tissue invasion of the human lung carcinoma cell line A549 and Calu-1. Cancer Res. 52: 3043-3047
142. 142 Liu G., Shuman M. A. and Cohen R. L. (1995) Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int. J. Cancer 60: 501-506
143. 143 Soff G. A., Sanderowitz J., Gately S., Verrusio E., Weiss I., Brem S. et al. (1995) Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J. Clin. Invest. 96: 2593-2600
144. 144 Carmeliet P., Schoojans L., Kiekens L., Ream B., Degen J. L., Bronson R. et al. (1994) Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368: 419-424
145. 145 Carmeliet P., Stassen J.-M., Schoojans L., Ream B., Van den Oord J. J., De Mol M. et al. (1993) Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J. Clin. Invest. 92: 2756-2760
146. 146 Bugge T. H., Suh T. T., Flick M. J., Daugherty C. C., Rømer J., Solberg H. et al. (1995) The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility. J. Biol. Chem. 270: 16886-16894
147. 147 Bugge T. H., Flick M. J., Daugherty C. C. and Degen J. L. (1995) Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 9: 794-807
148. 148 Zheng X., Saunders T. L., Camper S. A., Samuelson L. C. and Ginsburg D. (1995) Vitronectin is not essential for normal mammalian development and fertility. Proc. Natl. Acad. Sci. USA 92: 12426-12430
149. 149 Bugge T. H., Kombrinck K. W., Flick M. J., Daugherty C. C., Danton M. J. and Degen J. L. (1996) Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 87: 709-719
150. 150 Chen Z.-L. and Strickland S. (1997) Neuronal death in the hippocampus is promoted by plasmin-catalysed degradation of laminin. Cell 91: 917-925
151. 151 Bugge T. H., Flick M. J., Danton M. J., Daugherty C. C., Rømer J., Danø K. et al. (1996) Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc. Natl. Acad. Sci. USA 93: 5899-5904
152. 152 Barazzone C., Belin D., Piguet P. F., Vassalli J. D. and Sappino A. P. (1996) Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. J. Clin. Invest. 98: 2666-2673
153. 153 Eitzman D. T., McCoy R. D., Zheng X., Fay W. P., Shen T., Ginsburg D. et al. (1996) Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J. Clin. Invest. 97: 232-237
154. 154 Pinsky D. J., Liao H., Lawson C. A., Yan S. F., Chen J., Carmeliet P. et al. (1998) Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition. J. Clin. Invest. 102: 919-928
155. 155 Gyetko M. R., Chen G. H., McDonald R. A., Goodman R., Huffnagle G. B., Wilkinson C. C. et al. (1996) Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans: a murine transgenic model. J. Clin. Invest. 97: 1818-1826
156. 156 Shapiro R. L., Duquette J. G., Nunes I., Roses D. F., Harris M. N., Wilson E. L. et al. (1997) Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles. Am. J. Pathol. 150: 359-369
157. 157 Ploplis V. A., French E. L., Carmeliet P., Collen D. and Plow E. F. (1998) Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood 91: 2005-2009
158. 158 Duffy M. J., Reilly D., O'Grady P., O'Higgins N., Fennelly J. J., and Andreasen P. A. (1995) Tissue-type and urokinase-type plasminogen activator as prognostic markers in breast cancer. In: Fibrinolysis in Disease, pp. 14 18, Glass-Greenwalt P. (ed.), CRC Press, New York
159. 159 Heiss M. M., Allgayer H., Gruetzner K. U., Funke I., Babic R., Jauch K.-W. et al. (1995) Individual development and u-PA receptor expression of disseminated tumour cells in bone marrow: a reference to early disease in solid cancer. Nat. Med. 1: 1035-1038
160. 160 Solomayer E. F., Diel I. J., Wallwiener D., Bode S., Meyberg G., Sillem M. et al. (1997) Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Br. J. Cancer 76: 812-818
161. 161 Shapiro R. L., Duquette J. G., Roses D. F., Nunes I., Harris M. N., Kamino H. et al. (1996) Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res. 56: 3597-3604
162. 162 Sabapathy K. T., Pepper M. S., Kiefer F., Mohle-Steinlein U., Tacchini-Cottier F., Fetka I. et al. (1997) Polyoma middle T-induced vascular tumor formation: the role of the plasminogen activator/plasmin system. J. Cell Biol. 137: 953-963
163. 163 Bugge T. H., Kombrinck K. W., Xiao Q., Holmback K., Daugherty C. C., Witte D. P. et al. (1997) Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood 90: 4522-4531
164. 164 Bugge T. H., Lund L. R., Kombrinck K. K., Nielsen B. S., Holmback K., Drew A. F. et al. (1998) Reduced metastasis of polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 16: 3097-3104
165. 165 Yu H. and Schultz R. M. (1990) Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 ceils transfected with human urokinase sense and antisense genes. Cancer Res. 50: 7623-7633
166. 166 Evans D. M. and Lin P. L. (1995) Suppression of pulmonary metastases of rat mammary cancer by recombinant urokinase plasminogen activator inhibitor. Am. Surg. 61: 692-696
167. 167 Mueller B. M., Yu Y. B. and Laug W. E. (1995) Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc. Natl. Acad. Sci. USA 92: 205-209
168. 168 Ma D., Gerard R. D., Li X. Y., Alizadeh H. and Niederkorn J. Y. (1997) Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. Blood 90: 2738-2746
169. 169 Jankun J., Keck R. W., Skrzypczak-Jankun E. and Swiercz R. (1997) Inhibitors of urokinasc reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res. 57: 559-563
170. 170 Eitzman D. T., Krauss J. C, Shen T., Cui J. and Ginsburg D. (1996) Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 87: 4718-4722
171. 171 Quax P. H., Van Muijen G. N. P, Weening-Verhoeff E. J., Lund L. R., Danø K., Ruiter D. J. et al. (1991) Metastastic behaviour of human melanoma cell lines in nude mice correlated with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J. Cell Biol. 115: 191-199
172. 172 Bajou K., Noel A., Gerard R. D., Masson V., Brünner N., Holst-Hansen C. et al. (1998) Absence of host plasminogen activator inhibitor-1 prevents cancer invasion and vascularization. Nat. Med. 4: 923-928
173. 173 O'Reilly M. S., Holmgren L., Chen C. and Folkman J. (1996) Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2: 689-692
174. 174 Sim B. K., O'Reilly M. S., Liang H., Fortier A. H., He W., Madsen J. W. et al. (1997) A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res. 57: 1329-1334
175. 175 Wu Z., O'Reilly M. S., Folkman J. and Shing Y. (1997) Suppression of tumor growth with recombinant murine angiostatin. Biochem. Biophys. Res. Commun. 236: 651-654
176. 176 Cao Y., O'Reilly M. S., Marshall B., Flynn E., Ji R. W. and Folkman J. (1998) Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J. Clin. Invest. 101: 1055-1063
177. 177 De Vries T. J., Quax P. H. A., Denijn M., Verrijp K. N., Verheijen J. H., Verspaget H. W. et al. (1994) Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am. J. Pathol. 144: 70-81
178. 2-macroglobulin receptor in human breast carcinomas. Int. J. Cancer 66: 441-452
179. 179 Borgfeldt C., Casslén B., Liu C.-L., Hansson S., Lecander I. and Åstedt B. (1998) High tissue content of urokinase plasminogen activator (uPA) is associated with high stromal expression of uPA mRNA in poorly differentiated serous ovarian carcinoma. Int. J. Cancer 79: 588-595
180. 180 Danø K., Behrendt N., Brünner N., Ellis V., Ploug M. and Pyke C. (1994) The urokinase receptor: protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8[suppl. 1]: 189-203
181. 181 Rifkin D. B., Moscatelli D., Bizik J., Quarto N., Blei F., Dennis P. et al. (1990) Growth factor control of extracellular proteolysis. Cell Differ. Dev. 32: 313-318
182. 182 Min H. Y., Doyle L. V., Vitt C. R., Zandonella C. L., Stratton-Thomas J. R., Shuman M. A. et al. (1996) Urokinase receptor antogonists inhibit angiogcnesis and primary growth in syngeneic mice. Cancer Res. 56: 2428-2433
183. 183 Hildenbrand R., Dilger I., Horlin A. and Stutte H. J. (1995) Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer. Pathol. Res. Pract. 191: 403-409
184. 184 Hiraoka N., Allen E., Apel I. J., Gyetko M. R. and Weiss S. J. (1998) Matrix mctalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95: 365-377
185. 185 Cao Y., Ji R. W., Davidson D., Schaller J., Marti D., Sohndel S. et al. (1996) Kringle domains of human angiostatin: characterization of the anti-proliferative activity on endothelial cells. J. Biol. Chem. 271: 29461-29467
186. 186 Ke S. H., Coombs G. S., Tachias K., Corey D. R. and Madison E. L. (1997) Optimal subsite occupancy and design of a selective inhibitor of urokinase. J. Biol. Chem. 272: 20456-20462
187. 187 Goodson R. J., Doyle M. V., Kaufman S. E. and Rosenberg S. (1994) High affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Natl. Acad. Sci. USA 91: 7129-7133
188. 188 Nielsen L. S., Andreasen P. A., Grøndahl-Hansen J., Huang J.-Y., Kristensen P. and Danø K. (1986) Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells: inhibitor neutralization and one-step affinity purification. Thromb. Haemostasis 55: 206-212
189. 189 Keijer J., Linders M., Zonneveld A. J. van, Ehrlich H. J., Boer J. P. de, and Pannekoek H. (1991) The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance. Blood 78: 401-409
190. 190 Friederich P. W., Levi M., Biemond B. J., Charlton P., Templeton D., Zonneveld A. J. van, et al. (1997) Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits. Circulation 96: 916-921
191. 191 Björquist P., Ehnebom J., Inghardt T., Hansson L., Lindberg M., Linschoten M. et al. (1998) Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis. Biochemistry 37: 1227-1234
192. 192 Eitzman D. T., Fay W. P., Lawrence D. A., Francis-Chmura A. M., Shore J. D., Olson S. T. et al. (1995) Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J. Clin. Invest. 95: 2416-2420
193. 193 Urano T., Strandberg L., Johansson L. B. and Ny T. (1992) A substrate-like form of plasminogen-activator-inhibitor type 1: conversions between different forms by sodium dodecyl sulphate. Eur. J. Biochem. 209: 985-992
194. 194 Gårdsvoll H., Zonneveld A. J. van, Holm A., Eldering E., Meijer M. van, Danø K. et al. (1998) Selection of peptides that bind to plasminogen activator inhibitor 1 (PAI-1) using random peptide phage-display libraries. FEBS Lett. 431: 170-174
195. 195 Harris A. L. (1998) Are angiostatin and endostatin cures for cancer? Lancet 351: 1598-1599
196. 196 Sato T. N. (1998) A new approach to fighting cancer? Proc. Natl. Acad. Sci. USA 95: 5843-5844
197. 197 Aertgeerts K., De Bondi H. L., De Ranter C. and Declerck P. J. (1994) A model of the reactive form of plasminogen activator inhibitor-1. J. Struct. Biol. 113: 239-245